Íñigo Angulo‐Barturen

Author

Also Known As

Angulo-Barturen, Iñigo, Iigo Angulo-Barturen, Inigo Angulo-Barturen, Iñigo Angulo-Barturen, IÑIGO ANGULO-BARTUREN, Iñigo Angulo-Barturen, Iñigo Angulo-Barturen (47469), Iñigo Angulo-Barturén, Iñigo Angulo‐Barturen, Íñigo Angulo-Barturen

109

Publications

6.9K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (Spain)Medicines for Malaria Venture Swiss Tropical and Public Health Institute University of Basel Monash University

ÍA

About

Íñigo Angulo‐Barturen is an author at GlaxoSmithKline (Spain) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	25	2.5K
2	Biochemistry	15	16	936
3	Natural Sciences	14	15	878
4	Health Sciences	2	2	62
5	Public Health	1	1	68

Íñigo Angulo‐Barturen

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Chemical genetics of Plasmodium falciparum W. Armand Guiguemde, Anang A. Shelat, David C. Bouck, Nature BiologyBiochemical TaxonomyGeneticsMalariaMolecular Genetics	2010	565
A novel multiple-stage antimalarial agent that inhibits protein synthesis Beatriz Baragaña, Irene Hallyburton, Neil R. Norcross, Nature Antiparasitic AgentMedicineMalariaPharmacologyProtein Synthesis	2015	452
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria Margaret A. Phillips, Julie Lotharius, Kennan C. Marsh, Science Translational Medicine	2015	367
Quinolone-3-Diarylethers: A New Class of Antimalarial Drug Aaron Nilsen, Alexis N. LaCrue, Karen L. White, Science Translational Medicine	2013	296
Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent<i>Plasmodium falciparum</i>Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential José M. Coterón, María Marco, Jorge Esquivias, Journal of Medicinal Chemistry	2011	280
Antimalarial efficacy of MMV390048, an inhibitor of <i>Plasmodium</i> phosphatidylinositol 4-kinase Tanya Paquet, Claire Le Manach, Diego González Cabrera, Science Translational Medicine	2017	262
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of <i>Plasmodium</i> Marı́a Belén Jiménez-Dı́az, Daniel Ebert, Yandira G. Salinas, Proceedings of the National Academy of Sciences Phenotypic ScreeningAntiparasitic AgentMalariaImmunologyMolecular Biology	2014	238
Improved Murine Model of Malaria Using<i>Plasmodium falciparum</i>Competent Strains and Non-Myelodepleted NOD-<i>scid IL2R</i>γ<sup><i>null</i></sup>Mice Engrafted with Human Erythrocytes Marı́a Belén Jiménez-Dı́az, Teresa Mulet, Sara Viera, Antimicrobial Agents and Chemotherapy Drug TargetLaboratory ImmunologyAntiparasitic AgentMalariaImmunology	2009	187
A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission David A. Baker, Lindsay B. Stewart, Jonathan M. Large, Nature Communications	2017	173
A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes Íñigo Angulo‐Barturen, Marı́a Belén Jiménez-Dı́az, Teresa Mulet, PLoS ONE	2008	161

Page 1